Technical Data
T8180-15B
TRAIL, Recombinant, Human (TNF-Related Apoptosis Inducing Ligand, Apo2L, TL2, TNFSF10)
50ug
250ug
Growth Factors, Cytokines Storage: -70CShipping: Dry Ice
TRAIL, 114-281 aa, Human, Recombinant, E. coli

Recombinant human TRAIL was expressed in E.coli and purified by using conventional chromatography techniques.

TNF-related apoptosis-inducing ligand (TRAIL) belongs to the tumor necrosis factor (TNF) cytokine family and induces rapid apoptosis in a wide variety of tumor cell lines upon binding to the death-signalling receptors on the cell membrane. TRAIL binds to one of four receptors that have been identified in humans, including TRAIL-R1/DR4, TRAIL-R2/KILLER/DR5, TRAIL-R3/DcR1/TRID, and TRAIL-R4/DcR2/TRUNDD. Both DR4 and DR5 are pro-apoptotic receptors, which contain a cytoplasmic death domain and mediate apoptosis on binding to TRAIL. By contrast, TRID and TRUNDD do not contain a cytoplasmic death domain and block the function of TRAIL by competing with DR4 and DR5 for binding of TRAIL.

Molecular Weight: 23kD (211 aa)

Amino Acid Sequence:
MVRERGPQRV AAHITGTRGR SNTLSSPNSK NEKALGRKIN SWESSRSGHS FLSNLHLRNG
ELVIHEKGFY YIYSQTYFRF QEEIKENTKN DKQMVQYIYK YTSYPDPILL MKSARNSCWS
KDAEYGLYSI YQGGIFELKE NDRIFVSVTN EHLIDMDHEA SFFGAFLVG

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, aliquot to avoid repeated freezing and thawing and freeze at -70C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months.

Molecular Weight:
23kD (211 aa)
Source: Human, Recombinant, E. coli
Purity: 95% by SDS-PAGE
Concentration: ~1mg/ml
Form: Supplied as a liquid in 20mM Tris pH 7.5, 300mM NaCl, 0.1mM DTT, 10% glycerol.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Human Brain Astrocytes Mediate TRAIL-mediated Apoptosis after Treatment with IFN-gamma. Yonsei Med J 2006 Jun 30;47(3):354-8
2. [Influence of Chemotherapy on Expression of TRAIL in Primary Acute Leukemic Cells.] Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006 Jun;14(3):481-4
3. Improvement of Expression Level and Bioactivity of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Novel Zinc ion Feeding Strategy Lett 2006 Jun 24;
4. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006 Jun 23;
5. TRAIL-induced apoptosis proceeding from caspase-3-dependent and -independent pathways in distinct HeLa cells. Biochem Biophys Res Commun 2006 Jun 12;
6. [Effects of hTERT RNAi on apoptosis of hepatocellular carcinoma cells induced by TRAIL.] Zhonghua Gan Zang Bing Za Zhi 2006 Jun;14(6):435-40
7. Janssen EM, et al , (2005). Nature. Mar 3;434(7029):88-93
8. Nagane M , et al , (2001). Apoptosis. Jun;6(3):191-7.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.